Bladder Cancer Trials I saw on recent White interview that he commented on why bladder cancer was chosen rather than another type. Previously he had mentioned that bladder cancer was the most expensive to treat due to an 80% recurrence rate. This due in part to its anaerobic nature (lack of oxygen) in which bladder cancer thrives. This time, however, the primary reason given was the accessibility of the bladder via a catheter meaning it could be delivered to the patient very simply and without anesthesia. The application then of the laser light is the easiest part of the procedure. My question if I could ask it of management is whether, in a ph1/2 trial, is there any company constraint on reporting on progress of say the 1st 10 of 30 patients enrolled since it is not a blinded trial??